ICE Biopharma GmbH

I had the pleasure to attend a few weeks ago the JP Morgan Health Care Conference in San Francisco. In general, there was a positive mood around the conference with some positive M&A news and there was a genuine feeling that a lot of activity will happen in the Biopharma space in 2025. It was also good to learn about some new highly innovative biotech organizations that could make their mark in the years to come.   One of my personal highlights of the conference was to moderate one of the two major events of the INSEAD Alumni Club Healthcare with an impressive lineup of expert speakers: Robert Blum (President & CEO Cytokinetics), Mardi Dier (CFO Madrigal Pharmaceuticals), Margarida Duarte (CCO Deciphera Pharmaceuticals), Nancy Lundy, MA, ACC (VP of People and Culture, Crinetics Pharmaceuticals Pharmaceutical), Kirsten Detrick (Delegate Business Location Switzerland) and #Maria Fernandez (Trade Commissioner of Spain in Chicago)   It was a lively discussion as our panelists shared their real-world experiences, in building a European footprint for US biotech organizations. It was also great to see that countries such as Switzerland offer a great supportive ecosystem for US biotech to build a commercial hub and the same applies for Spain building a clinical hub.   Although a US biotech build-out in Europe should not be underestimated, our participants have been fully supportive in building an international footprint and would recommend other US biotech to follow this journey if certain things are in place:   -      If your US biotech organization has a good balance sheet and is ready to make the investment building an international organization -      Both the Board and the Executive Committee should be aligned and support the EU Build-Out -      Do a smaller staged build-out versus a full-sledged extensive build (unless you are really late to the European Launch)   Further it was also suggested that if a US biotech does not want to invest time and commitment in an EU Build to go other paths. One could be using a third party such as companies like ICE Biopharma GmbH that can be a commercialization partner in Europe building a launch organization for US biotech. What has been the most positive surprise for the representatives of the four US biotech on the panel has been the quality of candidates that they have encountered during their EU build. As the European talents are exposed to multiple European Health Care Systems, they bring a new skill set to the US biotech talents that are exposed primarily to one health care system. There was also a sense that by building a strong European footprint the US organization becomes stronger and more competitive.   As I left the conference the sun was still shinning, the consensus seems that 2025 could be a sunnier year for the Life Sciences industry INSEAD, INSEAD Alumni, INSEAD IDN, Korn Ferry, Korn Ferry Academy #JPMorgan Health Care Conference 2025

ICE Biopharma GmbH is looking forward to attending the JPM conference in San Francisco next week.